| Recent developments of C-4 substituted coumarin derivatives as anticancer agents J Dandriyal, R Singla, M Kumar, V Jaitak European journal of medicinal chemistry 119, 141-168, 2016 | 219 | 2016 |
| Coumarin derivatives as anticancer agents for lung cancer therapy: A review M Kumar, R Singla, J Dandriyal, V Jaitak Anti-Cancer Agents in Medicinal Chemistry (Formerly Current Medicinal …, 2018 | 45 | 2018 |
| Anticancer potential of some imidazole and fused imidazole derivatives: Exploring the mechanism via epidermal growth factor receptor (EGFR) inhibition S Kalra, G Joshi, M Kumar, S Arora, H Kaur, S Singh, A Munshi, R Kumar RSC Medicinal Chemistry 11 (8), 923-939, 2020 | 22 | 2020 |
| Design and Synthesis of Non-Covalent Imidazo[1,2-a]quinoxaline-Based Inhibitors of EGFR and Their Anti-Cancer Assessment M Kumar, G Joshi, S Arora, T Singh, S Biswas, N Sharma, ZR Bhat, ... Molecules 26 (5), 1490, 2021 | 21 | 2021 |
| Targeting the epidermal growth factor receptor with molecular degraders: State-of-the-art and future opportunities P Maity, J Chatterjee, KT Patil, S Arora, MK Katiyar, M Kumar, ... Journal of Medicinal Chemistry 66 (5), 3135-3172, 2023 | 14 | 2023 |
| Epidermal growth factor receptor and its trafficking regulation by acetylation: Implication in resistance and exploring the newer therapeutic avenues in cancer M Kumar, G Joshi, J Chatterjee, R Kumar Current Topics in Medicinal Chemistry 20 (12), 1105-1123, 2020 | 11 | 2020 |
| In Vivo Anticancer Evaluation of 6b, a Non-Covalent Imidazo[1,2-a]quinoxaline-Based Epidermal Growth Factor Receptor Inhibitor against Human Xenograft Tumor … ZR Bhat, M Kumar, N Sharma, UP Yadav, T Singh, G Joshi, B Pujala, ... Molecules 27 (17), 5540, 2022 | 4 | 2022 |
| Synthetic Modifications of Therapeutically Relevant Pre-assembled Cucurbitacins: Synthetic Strategies and Structure-Activity Relationships R Sharma, S Thakur, M Kumar, K Vamsi, S Jachak, IP Singh, R Kumar Journal of Molecular Structure, 138321, 2024 | 1 | 2024 |
| Imidazo[1,2‐a]Quinoxaline‐2‐Carbonitrile Derivative (RA‐22) Inhibits Self‐Renewal and Growth of Cancer Stem and Cancer Cells via Downregulating AKT Pathway P Kumar, U Prasad Yadav, G Joshi, S Arora, M Kumar, J Chatterjee, ... ChemistrySelect 9 (23), e202400223, 2024 | | 2024 |
| Design, synthesis, and anticancer assessment of structural analogues of (E)-1-((3, 4, 5-trimethoxybenzylidene) amino)-4-(3, 4, 5-trimethoxyphenyl) imidazo [1, 2-a] quinoxaline … M Kumar, KT Patil, P Maity, J Chatterjee, T Singh, G Joshi, S Singh, ... RSC Medicinal Chemistry, 2024 | | 2024 |
| Synthetic Approaches and Reactions of 2-(Arylidene)benzo[b]thiophen3(2H)one-1,1-dioxides S Barick, M Kumar, R and Kumar Mini-Reviews in Organic Chemistry, 2023 | | 2023 |
| FDA approved five-membered ring fused pyrimidine-based derivatives and their biological properties M Kumar, J Chatterjee, D Rani, R Kumar Fused Pyrimidine-Based Drug Discovery, 117-164, 2023 | | 2023 |
| The Future of COVID-19 Treatment S Arora, M Kumar, G Joshi, R Kumar COVID-19: Diagnosis and Management-Part II, 169, 2021 | | 2021 |
Raj Kumar, FRSCProfessor of Medicinal/Pharmaceutical Chemistry, Central University of Punjab在 cup.edu.in 的电子邮件经过验证
